Stock DNA
Pharmaceuticals & Biotechnology
CNY 39,141 Million (Large Cap)
53.00
NA
1.57%
-0.13
6.99%
4.28
Revenue and Profits:
Net Sales:
1,251 Million
(Quarterly Results - Jun 2026)
Net Profit:
165 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.3%
0%
1.3%
6 Months
-46.33%
0%
-46.33%
1 Year
-39.9%
0%
-39.9%
2 Years
-1.61%
0%
-1.61%
3 Years
11.48%
0%
11.48%
4 Years
36.57%
0%
36.57%
5 Years
13.63%
0%
13.63%
Shenzhen Salubris Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.36%
EBIT Growth (5y)
8.57%
EBIT to Interest (avg)
33.21
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.45
Tax Ratio
1.06%
Dividend Payout Ratio
94.11%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.84%
ROE (avg)
7.07%
Valuation key factors
Factor
Value
P/E Ratio
53
Industry P/E
Price to Book Value
3.67
EV to EBIT
64.94
EV to EBITDA
39.19
EV to Capital Employed
4.07
EV to Sales
7.18
PEG Ratio
7.07
Dividend Yield
1.82%
ROCE (Latest)
6.27%
ROE (Latest)
6.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
1,250.70
1,068.80
17.02%
Operating Profit (PBDIT) excl Other Income
265.00
262.00
1.15%
Interest
5.00
5.00
Exceptional Items
6.20
2.90
113.79%
Consolidate Net Profit
164.60
172.50
-4.58%
Operating Profit Margin (Excl OI)
124.00%
143.60%
-1.96%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 17.02% vs 12.30% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -4.58% vs 17.99% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,306.70
3,975.50
8.33%
Operating Profit (PBDIT) excl Other Income
1,065.00
1,080.40
-1.43%
Interest
22.00
17.70
24.29%
Exceptional Items
-114.40
-143.00
20.00%
Consolidate Net Profit
652.80
605.20
7.87%
Operating Profit Margin (Excl OI)
145.90%
168.90%
-2.30%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 8.33% vs 19.18% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 7.87% vs 4.20% in Dec 2024
About Shenzhen Salubris Pharmaceuticals Co., Ltd. 
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






